JP5727694B2 - Ｃ型肝炎の治療効果を予測するためのマーカー及びｃ型肝炎の治療効果の予測を行う方法並びにｃ型肝炎の予防又は治療剤 - Google Patents
Ｃ型肝炎の治療効果を予測するためのマーカー及びｃ型肝炎の治療効果の予測を行う方法並びにｃ型肝炎の予防又は治療剤 Download PDFInfo
- Publication number
- JP5727694B2 JP5727694B2 JP2009192615A JP2009192615A JP5727694B2 JP 5727694 B2 JP5727694 B2 JP 5727694B2 JP 2009192615 A JP2009192615 A JP 2009192615A JP 2009192615 A JP2009192615 A JP 2009192615A JP 5727694 B2 JP5727694 B2 JP 5727694B2
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- seq
- hepatitis
- primer
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009192615A JP5727694B2 (ja) | 2009-08-21 | 2009-08-21 | Ｃ型肝炎の治療効果を予測するためのマーカー及びｃ型肝炎の治療効果の予測を行う方法並びにｃ型肝炎の予防又は治療剤 |
| PCT/JP2010/063262 WO2011021508A1 (ja) | 2009-08-21 | 2010-08-05 | Ｃ型肝炎の治療効果を予測するためのマーカー及びｃ型肝炎の治療効果の予測を行う方法並びにｃ型肝炎の予防又は治療剤 |
| CN2010800365956A CN102482664A (zh) | 2009-08-21 | 2010-08-05 | 用于预测c型肝炎的治疗效果的标记物和预测c型肝炎的治疗效果的方法以及c型肝炎的预防或治疗剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009192615A JP5727694B2 (ja) | 2009-08-21 | 2009-08-21 | Ｃ型肝炎の治療効果を予測するためのマーカー及びｃ型肝炎の治療効果の予測を行う方法並びにｃ型肝炎の予防又は治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011041526A JP2011041526A (ja) | 2011-03-03 |
| JP2011041526A5 JP2011041526A5 (https=) | 2013-07-18 |
| JP5727694B2 true JP5727694B2 (ja) | 2015-06-03 |
Family
ID=43606963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009192615A Expired - Fee Related JP5727694B2 (ja) | 2009-08-21 | 2009-08-21 | Ｃ型肝炎の治療効果を予測するためのマーカー及びｃ型肝炎の治療効果の予測を行う方法並びにｃ型肝炎の予防又は治療剤 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP5727694B2 (https=) |
| CN (1) | CN102482664A (https=) |
| WO (1) | WO2011021508A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5656159B2 (ja) * | 2009-08-24 | 2015-01-21 | 独立行政法人理化学研究所 | インターフェロン療法の効果予測用マーカー |
| JP5787337B2 (ja) * | 2010-03-19 | 2015-09-30 | 公益財団法人ヒューマンサイエンス振興財団 | Ｃ型肝炎の治療効果を予測するためのマーカー群、検査方法及び検査用キット |
| AU2012233644A1 (en) * | 2011-03-31 | 2013-09-12 | Novartis Ag | Alisporivir to treat Hepatitis C virus infection |
| CN103074417B (zh) * | 2012-06-20 | 2015-06-24 | 宁波海尔施基因科技有限公司 | 一种丙型肝炎治疗用药指导的多重基因检测方法 |
| CN102816838A (zh) * | 2012-07-06 | 2012-12-12 | 吉林艾迪康医学检验所有限公司 | 用于检测丙型肝炎患者il28b snp12980275多态性的试剂盒 |
| EP3012326A4 (en) | 2013-03-26 | 2016-12-21 | Nippon Gene Co Ltd | PRIMER AND PROBE SET FOR IDENTIFYING GENPOLYMORPHISM AND USE THEREOF |
| JP6155750B2 (ja) * | 2013-03-27 | 2017-07-05 | 東洋紡株式会社 | ＳＮＰ（ｒｓ１１８８１２２２）を検出するためのプローブ |
-
2009
- 2009-08-21 JP JP2009192615A patent/JP5727694B2/ja not_active Expired - Fee Related
-
2010
- 2010-08-05 WO PCT/JP2010/063262 patent/WO2011021508A1/ja not_active Ceased
- 2010-08-05 CN CN2010800365956A patent/CN102482664A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011041526A (ja) | 2011-03-03 |
| WO2011021508A1 (ja) | 2011-02-24 |
| CN102482664A (zh) | 2012-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5727694B2 (ja) | Ｃ型肝炎の治療効果を予測するためのマーカー及びｃ型肝炎の治療効果の予測を行う方法並びにｃ型肝炎の予防又は治療剤 | |
| KR101633783B1 (ko) | Cyp3a5 및 cyp3a7 유전자 부위의 염기서열 다형성을 이용한 타크로리무스 혈중 약물 농도 예측 방법 | |
| CN102016031B (zh) | 高血压易感基因组的鉴定 | |
| WO2006123955A2 (en) | Methods for the assesssment of risk of developing lung cancer using analysis of genetic polymorphisms | |
| EP3008206B1 (en) | Method for detecting the susceptibility of a dog to hip dysplasia | |
| JP2013070660A (ja) | Ｃ型肝炎患者の経過予測方法 | |
| US20160076104A1 (en) | Methods and compositions for assessment of pulmonary function and disorders | |
| JP5787337B2 (ja) | Ｃ型肝炎の治療効果を予測するためのマーカー群、検査方法及び検査用キット | |
| KR101100437B1 (ko) | 단일염기 다형을 포함하는 대장암과 관련된 폴리뉴클레오티드, 그를 포함하는 마이크로어레이 및 진단 키트 및 그를 이용한 대장암의 진단방법 | |
| JP6245796B2 (ja) | 原発性胆汁性肝硬変の発症リスク予測マーカー、プローブ、プライマー及びキット並びに原発性胆汁性肝硬変の発症リスク予測方法 | |
| CN103882112B (zh) | 一种预测强直性脊柱炎易感性的试剂及方法 | |
| CN119177297B (zh) | 一种snp分子标记组合在鸡冠厚度辅助育种中的应用 | |
| CN105765077B (zh) | 测定抗甲状腺药物诱导的粒细胞缺乏症风险的检测方法以及测定用试剂盒 | |
| JP7824622B2 (ja) | Ｃｏｖｉｄ－１９の重症化の遺伝的要因を検出する方法及びキット | |
| KR20150092937A (ko) | 한국인의 고혈압 예측용 ｓｎｐ 마커 | |
| JP5416962B2 (ja) | 薬剤による光線過敏症の発症の危険性の判定方法 | |
| EP2566978A1 (en) | Antiviral treatment susceptibility gene and uses thereof | |
| JP5070552B2 (ja) | Ｃ型慢性肝炎治療効果予測のための検査方法及び検査用キット | |
| JP2004298011A (ja) | インターフェロンの治療効果を予測するための新規多型マーカー、プライマー、プローブおよびインターフェロンの治療効果を予測する方法 | |
| CN103710446B (zh) | 预测强直性脊柱炎易感性的试剂和方法 | |
| KR100695147B1 (ko) | 다중좌 마커를 이용한 2형 당뇨병의 진단방법, 2형당뇨병과 연관된 마커를 포함하는 폴리뉴클레오티드 및마이크로어레이 | |
| CN104313141B (zh) | 一种预测强直性脊柱炎易感性的检测试剂 | |
| JP5954724B2 (ja) | 第６染色体短腕２２領域または第９染色体長腕２１領域の一塩基多型に基づく肥満の検査方法 | |
| KR101168737B1 (ko) | Ｆａｎｃａ 유전자로부터 유래된 단일염기다형을 포함하는 폴리뉴클레오티드, 이를 포함하는 마이크로어레이 및 진단키트, 및 이를 이용한 분석방법 | |
| JP5791171B2 (ja) | 第１染色体長腕２４領域、ｎｅｕｒｌ遺伝子、またはｃｕｘ２遺伝子の一塩基多型に基づく不整脈の検査方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120816 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130530 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140404 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141027 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150123 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150130 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150311 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150403 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5727694 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |